Abstract 289P
Background
Inhibitors of the Receptor Activator of NFkB (RANK) pathway, such as denosumab, have been shown to prevent breast cancer (BC) in preclinical models by reducing proliferation and tumor cell survival. Recent studies suggest that RANK pathway inhibition enhances the anti-tumor immune response. This study aimed to evaluate the antiproliferative, proapoptotic (primary endpoints), and immunomodulatory activity (exploratory endpoint) of denosumab in early BC.
Methods
D-BIOMARK study (NCT03691311) was a randomized window-of-opportunity trial designed to evaluate the biological effects of single-agent denosumab in early BC. Sixty patients with early HER2-negative BC were enrolled, 2:1 randomization to experimental (two doses of 120mg of denosumab separated by 7 days before surgery) or control (no treatment) group. Paired samples (core-biopsy and surgical specimen) were obtained from each patient for comparison of Ki67 (proliferation), Cleaved Caspase-3 (cell survival), and tumor infiltrating lymphocytes (TILS) according to international guidelines. Pre vs. post values were compared using a paired t-test.
Results
A total of 58 evaluable patients were analyzed, 10 with triple-negative breast cancer (TNBC), 27 premenopausal and 31 postmenopausal. Denosumab reduced free RANKL (sRANK) levels in patient’s serum but did not reduce tumor cell survival or proliferation. Denosumab increased TILS in all patients, except TNBC (n=6) while differences in the control group did not reach statistical significance. When considering clinically significant increases in TILS (5% or 10%), no differences were found between both groups. No associations were found between basal sRANKL and an increase in TILS. Table: 289P
Response variable | Mean Pre | Mean Post | Control p-value | Mean Pre | Mean Post | Experimental p-value |
sRANKL pg/ml N=58 | 0.10 | 0.12 | 0.25 | 0.01 | 0.00 | <0.01 |
Ki-67 % N=58 | 24.52 | 29.19 | 0.05 | 20.59 | 25.24 | 0.01 |
CLEAVED-CASPASE 3 H-score N=58 | 1.66 | 2.24 | 0.05 | 2.56 | 1.98 | 0.24 |
TILS % N=58 | 7.42 | 12.24 | 0.06 | 7.35 | 12.94 | <0.01 |
TILS % within Luminal BC N=48 | 8.17 | 11.78 | 0.18 | 6.13 | 10.80 | 0.01 |
TILS % within TNBC N=10 | 4.250 | 14.250 | 0.24 | 13.667 | 24.000 | 0.08 |
TILS % within premenopausal patients with luminal BC N=26 | 10.68 | 12.60 | 0.64 | 7.31 | 12.73 | 0.05 |
TILS within postmenopausal patients with luminal BC =22 | 8.17 | 11.77 | 0.06 | 4.87 | 8.75 | 0.04 |
Conclusions
Denosumab did not affect tumor cell survival nor proliferation in early BC but may have an immunomodulatory effect that warrants further investigation.
Clinical trial identification
NCT03691311.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Amgen.
Disclosure
A. Vethencourt: Financial Interests, Personal, Invited Speaker, Presentation in clinical or research sessions as a speaker: Novartis, Eisai; Non-Financial Interests, Project Lead, GEICAM Grant “Balil-Pelegrí” 2021-2022, sponsored by theSpanish breast cancer research group GEICAM.: GEICAM; Non-Financial Interests, Advisory Board: SOLTI; Non-Financial Interests, Leadership Role, Participation in the TransGEICAM group, which is part of the Spanish breast cancer research group GEICAM (Not Paid): GEICAM; Other, Travel, Accommodations, Support for attending meetings: Pfizer, Lilly, Novartis, Roche. A. Stradella: Financial Interests, Personal, Advisory Board, Advisory about CAPITELLO 291 trial: AstraZeneca; Financial Interests, Personal, Advisory Board, Advisory on new activities for residents: Novartis; Financial Interests, Personal, Invited Speaker, Trastu-Deruxtecan clinical case meeting: Daiichi; Financial Interests, Personal, Invited Speaker, meeting on new data on cyclin inhibitors: Novartis. M.J. Gil: Financial Interests, Personal, Advisory Board: Daiichi; Pfizer; Novartis, Gilead; Palex; Seagen; Roche y Pierre-Fabre. S. Pernas Simon: Financial Interests, Personal, Advisory Board: SeaGen, AstraZeneca- Daiichi Sankyo, Pierre-Fabre, Pfizer; Financial Interests, Personal, Invited Speaker: Lilly, Novartis, Eisai, Roche; Financial Interests, Institutional, Local PI: AstraZeneca, Novartis, Daiichi Sankyo; Non-Financial Interests, Member of Board of Directors: SOLTI. E. Gonzalez-Suarez: Financial Interests, Personal and Institutional, Coordinating PI: Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
252P - Adjuvant chemotherapy in T1a/bN0 breast cancer patients with high oncotype DX recurrence scores (RS>25)
Presenter: Daniela Katz
Session: Poster session 02
253P - Is 6-weekly administration of pembrolizumab in combination with chemotherapy for early triple-negative breast cancer safe? A real-world early comparison of q6w versus q3w administration of pembrolizumab in two large cancer centres in the UK
Presenter: Vasileios Angelis
Session: Poster session 02
254P - Effects of delaying adjuvant chemotherapy initiation on clinical outcomes in early triple-negative breast cancer patients
Presenter: Maria Eleni Hatzipanagiotou
Session: Poster session 02
255P - Prognostic stratification capacity of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
Presenter: Nicolas Roussot
Session: Poster session 02
256P - Evolution and risk stratification of adjuvant treatment strategies for early breast cancer: A Chinese perspective based on a national cancer database
Presenter: Ying Fan
Session: Poster session 02
257P - The characteristics of HER2-positive microinvasive breast cancer and the necessity of chemotherapy and anti-HER2 therapy in these patients: A real-world study
Presenter: Bo Lan
Session: Poster session 02
258P - Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for high-risk early-stage triple-negative breast cancer in Colombia
Presenter: Ricardo Brugés Maya
Session: Poster session 02
259P - Adjuvant doxorubicin-cyclophosphamide in early-stage breast cancer provides long-term cardiac safety
Presenter: Thiti Susiriwatananont
Session: Poster session 02
260P - Oncology efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy
Presenter: Hee Jun Choi
Session: Poster session 02
261P - Dysregulation of immune checkpoint proteins in newly- diagnosed early breast cancer patients undergoing neoadjuvant chemotherapy: A comparison between TNBC and non-TNBC patients
Presenter: Bernardo Rapoport
Session: Poster session 02